{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T21:01:00Z","timestamp":1768251660813,"version":"3.49.0"},"reference-count":43,"publisher":"Scientific Scholar","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Dermatol Venereol Leprol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/ijdvl.ijdvl_791_18","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T06:27:59Z","timestamp":1573540079000},"page":"1","source":"Crossref","is-referenced-by-count":7,"title":["Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy in patients with psoriasis and psoriatic arthritis in Indian population"],"prefix":"10.25259","volume":"86","author":[{"given":"SibaP","family":"Raychaudhuri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumajyoti","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saumya","family":"Panda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byungsoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SmritiK","family":"Raychaudhuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asutosh","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"key-10.4103\/0378-6323.270775-1","first-page":"550","article-title":"Psoriasis in the tropics: An epidemiological survey","author":"Okhandiar","year":"1963","journal-title":"J Indian Med Assoc"},{"key":"key-10.4103\/0378-6323.270775-2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3899\/jrheum.111244","article-title":"Comorbidities of psoriatic arthritis \u2013 Metabolic syndrome and prevention: A report from the GRAPPA 2010 annual meeting","author":"Raychaudhuri","year":"2012","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0378-6323.270775-3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaut.2016.10.009","article-title":"Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies","author":"Raychaudhuri","year":"2017","journal-title":"J Autoimmun"},{"key":"key-10.4103\/0378-6323.270775-4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.autrev.2009.08.006","article-title":"Incidence and nature of infectious disease in patients treated with anti-TNF agents","author":"Raychaudhuri","year":"2009","journal-title":"Autoimmun Rev"},{"key":"key-10.4103\/0378-6323.270775-5","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0378-6323.270775-6","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology biologics register","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0378-6323.270775-7","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1002\/art.11301","article-title":"Infections and anti-tumor necrosis factor alpha therapy","author":"Ellerin","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0378-6323.270775-8","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report","author":"G\u00f3mez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0378-6323.270775-9","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.270775-10","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): Effects of RA itself and of tumor necrosis factor blockers","author":"Seong","year":"2007","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0378-6323.270775-11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0378-6323.270775-12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","article-title":"Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor","author":"Mohan","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0378-6323.270775-13","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/0378-6323.270775-14","unstructured":"Global Tuberculosis report 2017 - World Health Organization. Available from: https:\/\/www.who.int\/tb\/publications\/global_report\/gtbr2017_main_text.pdf. [Last accessed on 2018 Jun 20]."},{"key":"key-10.4103\/0378-6323.270775-15","unstructured":"TB India 2017: Revised National TB Control Programme Annual Status Report. Available from: http:\/\/www.tbonline.info\/posts\/2017\/6\/4\/tb-india-2017-rntcp-annual-status-report\/. [Last accessed on 2018 Sep 01]."},{"key":"key-10.4103\/0378-6323.270775-16","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/jgh.13669","article-title":"Infliximab-induced tuberculosis in patients with UC: Experience from India \u2013 A country with high prevalence of tuberculosis","author":"Puri","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"key-10.4103\/0378-6323.270775-17","first-page":"78","article-title":"Clinical experience with infliximab in spondyloarthropathy: An open label study on fourteen patients","author":"Grover","year":"2005","journal-title":"J Indian Rheumatol Assoc"},{"key":"key-10.4103\/0378-6323.270775-18","first-page":"11:1 (Abstract)","article-title":"Safety and efficacy profile of infliximab in inflammatory arthritis","author":"Narayanan","year":"2003","journal-title":"Indian Rheumatism Assoc"},{"key":"key-10.4103\/0378-6323.270775-19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1479-8077.2006.00188.x","article-title":"Experience with anti-tumor necrosis factor-\u03b1 therapy in India","author":"Kumar","year":"2006","journal-title":"APLAR J Rheumatol"},{"key":"key-10.4103\/0378-6323.270775-20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/1756-185X.12188","article-title":"Risk of tuberculosis with anti-tumor necrosis factor-\u03b1 therapy: Substantially higher number of patients at risk in Asia","author":"Navarra","year":"2014","journal-title":"Int J Rheumatic Dis"},{"key":"key-10.4103\/0378-6323.270775-21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5217\/ir.2016.14.2.183","article-title":"Rectal tuberculosis after infliximab therapy despite negative screening for latent tuberculosis in a patient with ulcerative colitis","author":"Singh","year":"2016","journal-title":"Intest Res"},{"key":"key-10.4103\/0378-6323.270775-22","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1468-3083.2010.03836.x","article-title":"Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: Report of a case series with 144 patients","author":"S\u00e1nchez-Moya","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/0378-6323.270775-23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3346\/jkms.2015.30.2.173","article-title":"The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-\u03b1 blockers","author":"Byun","year":"2015","journal-title":"J Korean Med Sci"},{"key":"key-10.4103\/0378-6323.270775-24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.rbr.2017.05.003","article-title":"Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: Data from the Brazilian registry of biological therapies in rheumatic diseases (Registro Brasileiro de Monitora\u00e7\u00e3o de Terapias Biol\u00f3gicas \u2013 Biobadabrasil)","author":"Yonekura","year":"2017","journal-title":"Rev Bras Reumatol Engl Ed"},{"key":"key-10.4103\/0378-6323.270775-25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/injr.injr_40_17","article-title":"Clinical experience with two etanercept biosimilars in Indian patients with spondyloarthritis","author":"Kumar","year":"2017","journal-title":"Indian J Rheumatol","ISSN":"https:\/\/id.crossref.org\/issn\/0973-3698","issn-type":"print"},{"key":"key-10.4103\/0378-6323.270775-26","unstructured":"TB India 2016. Revised National TB Control Program. Annual Status Report. Available from: https:\/\/tbcindia.gov.in\/index1. [Last accessed on 2018 Jun 20]."},{"key":"key-10.4103\/0378-6323.270775-27","unstructured":"World Health Organisation. WHO Tuberculosis. Guidelines on the Management of Latent Tuberculosis Infection. World Health Organisation; 2015. Available from: https:\/\/www.who.int\/tb\/publications\/latent-tuberculosis-infection\/en\/. [Last accessed on 2018 Jul 20]."},{"key":"key-10.4103\/0378-6323.270775-28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3121\/cmr.2.3.191","article-title":"Testing for latent tuberculosis","author":"Ayub","year":"2004","journal-title":"Clin Med Res"},{"key":"key-10.4103\/0378-6323.270775-29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/2229-5178.93479","article-title":"Mantoux test and its interpretation","author":"Nayak","year":"2012","journal-title":"Indian Dermatol Online J","ISSN":"https:\/\/id.crossref.org\/issn\/2229-5178","issn-type":"print"},{"key":"key-10.4103\/0378-6323.270775-30","doi-asserted-by":"crossref","first-page":"e0190106","DOI":"10.1371\/journal.pone.0190106","article-title":"CD14-159C\/T polymorphism in the development of delayed skin hypersensitivity to tuberculin","author":"Druszczynska","year":"2017","journal-title":"PLoS One"},{"key":"key-10.4103\/0378-6323.270775-31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.micres.2006.11.016","article-title":"A protein linkage map of the ESAT-6 secretion system 1 (ESX-1) of Mycobacterium tuberculosis","author":"Teutschbein","year":"2009","journal-title":"Microbiol Res"},{"key":"key-10.4103\/0378-6323.270775-32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1128\/CMR.00034-13","article-title":"Gamma interferon release assays for detection of Mycobacterium tuberculosis infection","author":"Pai","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"key-10.4103\/0378-6323.270775-33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1465-9921-7-77","article-title":"Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons","author":"Diel","year":"2006","journal-title":"Respir Res"},{"key":"key-10.4103\/0378-6323.270775-34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4103\/0971-3026.29096","article-title":"Is HRCT reliable in determining disease activity in pulmonary tuberculosis?","author":"Raniga","year":"2006","journal-title":"Indian J Radiol Imaging","ISSN":"https:\/\/id.crossref.org\/issn\/0971-3026","issn-type":"print"},{"key":"key-10.4103\/0378-6323.270775-35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4103\/0971-3026.161431","article-title":"Chest tuberculosis: Radiological review and imaging recommendations","author":"Bhalla","year":"2015","journal-title":"Indian J Radiol Imaging","ISSN":"https:\/\/id.crossref.org\/issn\/0971-3026","issn-type":"print"},{"key":"key-10.4103\/0378-6323.270775-36","unstructured":"CDC Latent TB Treatment. Treatment for Latent TB Infection. Available from: http:\/\/www.cdc.gov\/tb\/topic\/treatment\/ltbi.htm. [Last accessed on 2018 Aug 15]."},{"key":"key-10.4103\/0378-6323.270775-37","unstructured":"Center for Disease Control and Prevention. Latent Tuberculosis Infection: A Guide for Primary Health Care Providers. Atlanta, USA: Center for Disease Control and Prevention; 2014. Available from: https:\/\/www.cdc.gov\/tb\/publications\/ltbi\/default.htm. [Last accessed on 2018 Aug 12]."},{"key":"key-10.4103\/0378-6323.270775-38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ebch.1962","article-title":"Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB","author":"Sharma","year":"2014","journal-title":"Evid Based Child Health"},{"key":"key-10.4103\/0378-6323.270775-39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4103\/2229-5178.193915","article-title":"Biologics use in Indian psoriasis patients","author":"Rajagopalan","year":"2016","journal-title":"Indian Dermatol Online J","ISSN":"https:\/\/id.crossref.org\/issn\/2229-5178","issn-type":"print"},{"key":"key-10.4103\/0378-6323.270775-40","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","article-title":"British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009","author":"Smith","year":"2009","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.270775-41","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0140-6736(06)69063-6","article-title":"Blood tests for diagnosis of tuberculosis","author":"Phadke","year":"2006","journal-title":"Lancet"},{"key":"key-10.4103\/0378-6323.270775-42","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3899\/jrheum.081042","article-title":"Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India \u2013 An audit report","author":"Malaviya","year":"2009","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0378-6323.270775-43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1479-8077.2006.00181.x","article-title":"Guidelines for tuberculosis prophylaxis during anti-tumour necrosis factor-\u03b1 treatment: Indian Rheumatology Association","author":"Handa","year":"2006","journal-title":"APLAR J Rheumatol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T10:40:02Z","timestamp":1611916802000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijdvl.com\/risk-of-tuberculosis-with-anti-tumor-necrosis-factor-alpha-therapy-in-patients-with-psoriasis-and-psoriatic-arthritis-in-indian-population\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["270775"],"URL":"https:\/\/doi.org\/10.4103\/ijdvl.ijdvl_791_18","relation":{},"ISSN":["0378-6323"],"issn-type":[{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}